Regadenoson

證據等級: L5

預測適應症: 4 個

Regadenoson: From Pharmacologic Cardiac Stress Agent to Anaphylaxis (Likely Artifact)

One-Sentence Summary

Regadenoson is an adenosine A2A receptor agonist used internationally as a pharmacologic stress agent for cardiac perfusion imaging; no Taiwan/Norway-approved indication or MOA record is currently on file. The TxGNN model's top prediction is Anaphylaxis, but this signal is most plausibly a reverse-causality artifact — anaphylactoid/hypersensitivity reaction is a known adverse effect of regadenoson, not a treatment target. Evidence support is minimal: 1 clinical trial (graded irrelevant, "C") and 0 supporting publications.

Quick Overview

Item	Content
Original Indication	Not available in evidence pack (drug not licensed in Taiwan/Norway; internationally used as a pharmacologic cardiac stress-testing agent)
Predicted New Indication	Anaphylaxis
TxGNN Prediction Score	99.85%
Evidence Level	L5 (model prediction only, no supportive real-world evidence)
Norway Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (Data Gap). Based on available evidence, regadenoson is an adenosine A2A receptor agonist. In the one identified clinical trial context, it is used as a pharmacologic stress agent to simulate exercise-induced cardiac blood flow changes during MRI/perfusion imaging — not as a disease-modifying therapeutic.

Critically, the repurposing rationale provided in the evidence pack itself flags that hypersensitivity/anaphylactoid reactions are a known, labeled adverse effect of regadenoson. This means the TxGNN prediction linking regadenoson to "anaphylaxis" most likely reflects a drug-causes-adverse-event relationship embedded in the knowledge graph, rather than a drug-treats-disease relationship. This is a well-recognized failure mode for embedding-based prediction models (reverse causality / polarity confusion) and should not be interpreted as a genuine treatment signal.

The remaining three candidates (food-dependent exercise-induced anaphylaxis, esotropia, pseudoallergy) show no identifiable mechanistic link to A2A receptor pharmacology, and pseudoallergy has the same reverse-causality concern as the top prediction. None of the four candidates are supported by clinical trials or literature.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06854458	N/A	Recruiting	1000	Multicenter stress cardiac MRI perfusion imaging study; regadenoson used as a pharmacologic stress agent to assess coronary blood flow. Not designed to treat anaphylaxis — any anaphylaxis events would be safety monitoring endpoints, not efficacy endpoints. Relevance grade: C (does not support the predicted indication).

Literature Evidence

Currently no related literature available.

Norway Market Information

Regadenoson currently has no marketing authorization on file (0 licenses; market status: Not marketed). No product table can be generated.

Safety Considerations

Key Warnings: Not available in structured safety data (Data Gap). Note, however, that the repurposing rationale explicitly identifies hypersensitivity/anaphylactoid reaction as a known labeled risk of regadenoson — this is directly relevant to interpreting the top-ranked prediction and should be treated as a safety signal, not a treatment opportunity.
Drug Interactions: Query returned no results (not found).

Please refer to the package insert for complete safety information once available (see Data Gap DG001, currently marked Blocking).

Conclusion and Next Steps

Decision: Hold

Rationale: All four predicted indications are Evidence Level L5 (model prediction only), with either irrelevant (Grade C) or no clinical trial support and zero supporting literature. The top-ranked candidate, anaphylaxis, is very likely a reverse-causality artifact reflecting a known adverse drug reaction rather than a genuine therapeutic relationship, and the drug is not currently marketed in Norway or Taiwan.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain official label warnings/contraindications from TFDA before any safety pre-screening can begin
Resolve DG002 (High): confirm mechanism of action via DrugBank to properly evaluate mechanistic plausibility
Independent verification of TxGNN edge polarity (treats vs. causes) for the anaphylaxis prediction before further investment
If pursued, seek prospective clinical or case-report evidence specifically evaluating a therapeutic (not adverse) relationship between regadenoson and any of the four candidate indications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.